By Peter Geschek:
In its first full year on the market, in 2012, Johnson & Johnson's prostate cancer medicine Zytiga generated $961 million in revenues which make it a "near blockbuster". (A drug is considered blockbuster above $1 billion in sales).Zytiga is the most successful oral oncology drug launch in history. It is now approved in 65 countries and helped a huge number of men everywhere.
By The Burrill Report:
By Vinay Singh
Johnson & Johnson (JNJ) released interim data from a late-stage study that showed its prostate cancer drug, Zytiga, improved survival of men with less advanced forms of the disease. The newly released data may help expand the indication of the already approved drug to treat a larger patient pool.
ByEmerging Equities:These are exciting times for Johnson & Johnson (JNJ) with FDA product approvals setting the stage for higher growth. Recently the FDA approved Johnson & Johnson's drugs Zytiga for prostrate cancer, Invokana for type 2 diabetes, and Invega for schizophrenia.
Medivation Inc. (MDVN) and ASTELLAS PHARMA INC.’s (ALPMY) jointly developed drug, Xtandi, is likely to make a dent in the sales of Johnson & Johnson’s (JNJ) drug Zytiga given its more favorable safety profile in treating pre-chemotherapy prostate cancer patients.
Myriad Genetics (MYGN) shares were up more than 11% yesterday to close at a 52-week high of $35.03 yesterday, after the company published data in the Journal of Urology proving that its recurring prostate cancer detection test, Prolaris, yielded positive results.
By Brian Gilmartin:Johnson & Johnson, (JNJ) the large-cap, blue-chip, pharmaceutical and consumer brand giant reports Tuesday morning, October 16th before the bell, with analyst consensus expecting $1.21 in earnings per share on $16.93 bl in revenues for expected year-over-year growth of -2% and +6% respectively.